International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
HIV status is not associated with SARS-CoV-2 viral load and longer duration of infection among people with well-controlled HIV and high COVID-19 vaccine coverage.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Deb Didhiti, Heidari Mohammad Eghbal, Kizito Balladiah, Kesamang Monamodi, Matila Tebogo, Matsheka Maitshwarelo, Niemann Stefan, Shin Sanghyuk S, Modongo Chawangwa
Аннотация
OBJECTIVES: This cohort study examined the associations between HIV status with SARS-CoV-2 viral load and duration of infection in a setting with high antiretroviral therapy (ART) coverage.
METHODS: COVID-19 patients enrolled from public health clinics in Gaborone, Botswana underwent weekly serial testing for SARS-CoV-2. RT-PCR cycle threshold (Ct) value was used as a proxy measure of viral load. Multiple linear regression and Cox proportional-hazards models were used to determine the associations between HIV with Ct and time to SARS-CoV-2 negativity, respectively.
RESULTS: Of the 486 enrolled participants, 88.7% were vaccinated for COVID-19, and 26.1% were people living with HIV (PLWH) with a mean CD4+ T cell count of 715 cells/µL and 86.6% taking ARTs. Mean Ct values were similar across HIV and CD4+ T cell categories (P = 0.76). Time to negativity was similar for PLWH with CD4+ T cell count ≥500 cells/µL (adjusted hazard ratio [aHR] = 1.00; 95% confidence interval [CI] = 0.61, 1.64) and <500 cells/µL (aHR = 1.24; 95% CI: 0.88, 1.75) compared to people without HIV.
CONCLUSIONS: In a setting with well-controlled HIV and high COVID-19 vaccine coverage, HIV status was not associated with SARS-CoV-2 viral load or infection duration.
METHODS: COVID-19 patients enrolled from public health clinics in Gaborone, Botswana underwent weekly serial testing for SARS-CoV-2. RT-PCR cycle threshold (Ct) value was used as a proxy measure of viral load. Multiple linear regression and Cox proportional-hazards models were used to determine the associations between HIV with Ct and time to SARS-CoV-2 negativity, respectively.
RESULTS: Of the 486 enrolled participants, 88.7% were vaccinated for COVID-19, and 26.1% were people living with HIV (PLWH) with a mean CD4+ T cell count of 715 cells/µL and 86.6% taking ARTs. Mean Ct values were similar across HIV and CD4+ T cell categories (P = 0.76). Time to negativity was similar for PLWH with CD4+ T cell count ≥500 cells/µL (adjusted hazard ratio [aHR] = 1.00; 95% confidence interval [CI] = 0.61, 1.64) and <500 cells/µL (aHR = 1.24; 95% CI: 0.88, 1.75) compared to people without HIV.
CONCLUSIONS: In a setting with well-controlled HIV and high COVID-19 vaccine coverage, HIV status was not associated with SARS-CoV-2 viral load or infection duration.